521. Hospital admissions associated to respiratory viruses. 2014-2015 season. Valencia Hospital Network for the Study of influenza and other Respiratory Viruses (Spain)
Session: Poster Abstract Session: Respiratory Infections: Viral (non Influenza)
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • HBTNCC 2014-2015 IDWeek poster 521 ARV admissions all ages.ppt.pdf (1.3 MB)
  • Background:

    Burden of disease associated with respiratory viruses (RV) is poorly defined. The aim of this study was to describe the incidence of admissions with RV, by age and virus.

    Methods:

    Prospective active surveillance study of consecutive admissions with RV confirmed infection in ten hospitals (catchment area 2,351,526 inhabitants) in the Valencia region (Spain).

    We identified all patients admitted with symptoms possibly associated with a recent viral infection. After consent, we obtained nasopharyngeal swabs that were tested by RT-PCR. We obtained population data from the health care Population Information System.

    Results:

    From epidemiological week 45-2014 to 13-2015, we ascertained 9,363 eligible admissions, 87% consented to be included, 4,429 (47%) met all inclusion criteria, valid samples were available from 4,423 (47%).

    Overall, 1,689 (38%) were positive for a RV: 741 (44%) influenza, 363 (21%) rhino/enterovirus, 226 (13%) respiratory syncytial virus, 134 (8%), coronavirus, 115 metapneumovirus (7%), 79 (5%) mixed infections and 1% or less for bocavirus, parainfluenza or adenovirus.

    Admission rates with a RV were 1,575 per 100,000 inhabitants <1 years old, 210 in those 1 to 4 years old, and 232 per 100,000 in patients aged ≥ 65 (Figure 1).

    A(H3N2) was predominant (613, 83% of all influenza) with admission rates of 98 per 100,000 inhabitants <1 years old and 57, 139 and 252 admissions per 100,000 in patients 65-74, 75-84 and ≥ 85 years old, respectively. RSV admission rates were 679 per 100,000 inhabitants <1, 50 per 100,000 in those 1 to 4 years old, and 6, 15 and 26 per 100,000 in patients aged 65-74, 75-84 and ≥ 85, respectively. Rhino/enterovirus were associated with 326 admissions per 100,000 inhabitants < 1 year old, 55 per 100,000 1 to 4, and 21, 53 and 87 per 100,000 in patients aged 65-74, 75-84 and ≥ 85, respectively

    Conclusion:

    The greatest burden of disease due to admissions with respiratory virus infection was observed mainly in children under one year of age with 1.6 % children in their first year of life being admitted at least once. The incidence of admissions in the group of 1 to 4 years of age was similar to that experienced in the group aged 65 or more.

    Figure 1. Age specific admission rates.

    Joan Puig-Barberà, MD, MPH, PhD1,2, Ainara Mira-Iglesias, MSc.1, Miguel Tortajada-Girbés, MD3, F. Xavier López-Labrador, PhD1,4, Ángel Belenguer-Varea, MD5, Concha Carratalà-Munuera, MD. , PhD6,7, Mario Carballido-Fernández, MD8, Ramón Limón-Ramírez, MD9, Empar Carbonell-Franco, MD10, Joan Mollar-Maseres, MD11, Maria Del Carmen Otero-Reigada, MD11, Germán Schwarz-Chavarri, MD12, José Tuells-Hernández, MD13 and Vicente Gil-Guillén, MD. , PhD7,14, (1)Fundación para el Fomento de la investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain, (2)Centro de Salud Pública de Castellón, Castellón, Spain, (3)Hospital Universitario Doctor Peset, Valencia, Spain, (4)Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain, (5)Hospital Universitario de La Ribera, Valencia, Spain, (6)Hospital San Juan, Alicante, Spain, (7)Departamento De Medicina Clínica, Cátedra De Medicina De Familia.Universidad Miguel Hernández, Alicante, Spain, (8)Hospital General de Castellón, Castellón, Spain, (9)Hospital de la Plana, Castellón, Spain, (10)Hospital Arnau de Vilanova, Valencia, Spain, (11)Hospital Universitario y Politécnico La Fe, Valencia, Spain, (12)Hospital General de Alicante, Alicante, Spain, (13)Hospital Universitario del Vinalopó, Alicante, Spain, (14)Hospital de Elda, Alicante, Spain

    Disclosures:

    J. Puig-Barberà, Sanofi Pasteur Institution: funding for the study , Research support

    A. Mira-Iglesias, Sanofi Pasteur Institution: funding for the study , Research support

    M. Tortajada-Girbés, Sanofi Pasteur Institution: funding for the study , Research support

    F. X. López-Labrador, Sanofi Pasteur Institution: funding for the study , Research support

    Belenguer-Varea, Sanofi Pasteur Institution: funding for the study , Research support

    C. Carratalà-Munuera, Sanofi Pasteur Institution: funding for the study , Research support

    M. Carballido-Fernández, Sanofi Pasteur Institution: funding for the study , Research support

    R. Limón-Ramírez, Sanofi Pasteur Institution: funding for the study , Research support

    E. Carbonell-Franco, Sanofi Pasteur Institution: funding for the study , Research support

    J. Mollar-Maseres, Sanofi Pasteur Institution: funding for the study , Research support

    M. D. C. Otero-Reigada, Sanofi Pasteur Institution: funding for the study , Research support

    G. Schwarz-Chavarri, Sanofi Pasteur Institution: funding for the study , Research support

    J. Tuells-Hernández, Sanofi Pasteur Institution: funding for the study , Research support

    V. Gil-Guillén, Sanofi Pasteur Institution: funding for the study , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.